AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36420633 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/day
Number of subjects: 24
Study 36420633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 0
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: FG
Number of subjects: 0
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: HCadjBMI
Number of subjects: 0
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: FI
Number of subjects: 0
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: WCadjBMI
Number of subjects: 0
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 0
Study 32970198 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel BMD
Number of subjects: 0
Study 36283750 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured adipose derived mesenchymal stem cells (ADMSCs) combined with hyaluronic acid (HA) hydrogel
Number of subjects: 100
Study 36283750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34386961 — intervention group
Group type: EXPERIMENTAL
Intervention: CycH8a ligand selected from a randomized 6-mer library; cyclization achieved through a cysteine–AcrK linker
Number of subjects: 0
Study 33973407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led consultation
Number of subjects: 280
Study 33973407 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist follow-up
Number of subjects: 280
Study 32868028 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) exercise (twice/week for 24 weeks)
Number of subjects: 43
Study 32868028 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium and vitamin D supplementation only)
Number of subjects: 43
Study 34510197 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen-Strong programme and standard sexual education
Number of subjects: 66
Study 34510197 — intervention group
Group type: COMPARATOR
Intervention: Standard sexual education
Number of subjects: 66
Study 34021094 — intervention group
Group type: EXPERIMENTAL
Intervention: 10INT
Number of subjects: 11
Study 34021094 — intervention group
Group type: EXPERIMENTAL
Intervention: CON
Number of subjects: 11
Study 34021094 — intervention group
Group type: EXPERIMENTAL
Intervention: 10CON
Number of subjects: 11
Study 34021094 — intervention group
Group type: EXPERIMENTAL
Intervention: 25CON
Number of subjects: 11
Study 34021094 — intervention group
Group type: EXPERIMENTAL
Intervention: 25INT
Number of subjects: 11
Study 34337677 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews placed at 90° insertion angle
Number of subjects: 25
Study 34337677 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews placed at 45° insertion angle
Number of subjects: 25
Study 34337677 — intervention group
Group type: COMPARATOR
Intervention: Miniscrews at 90°
Number of subjects: 25
Study 34337677 — intervention group
Group type: COMPARATOR
Intervention: Miniscrews at 45°
Number of subjects: 25
Study 32250572 — intervention group
Group type: COMPARATOR
Intervention: Tongue brushing (Intervention I)
Number of subjects: 32
Study 32250572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care tablet containing kiwifruit powder (Intervention II)
Number of subjects: 32
Study 32250572 — intervention group
Group type: EXPERIMENTAL
Intervention: Three oral care tablets (Intervention III)
Number of subjects: 32
Study 34705573 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiotherapy (PMRT)
Number of subjects: 1011
Study 33309489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 128
Study 33309489 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 128
Study 34511090 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM‐LDH‐THA
Number of subjects: 75
Study 34511090 — intervention group
Group type: COMPARATOR
Intervention: MoM‐HR
Number of subjects: 75
Study 32585854 — intervention group
Group type: EXPERIMENTAL
Intervention: Almega®PL (1 g/day)
Number of subjects: 120
Study 32585854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36071165 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy matched to genomic alteration
Number of subjects: 1462
Study 36071165 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib for patients with germline BRCA1/2 mutations
Number of subjects: 1462
Study 34486130 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 200
Study 34486130 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study 32845589 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate (HP) 0.01% lotion
Number of subjects: 430
Study 32845589 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 430
Study 33721986 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training
Number of subjects: 45
Study 33721986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed strength training
Number of subjects: 45
Study 33721986 — intervention group
Group type: COMPARATOR
Intervention: Control (static stretching)
Number of subjects: 45
Study 34538087 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (platelet function monitoring-guided adjustment of antiplatelet therapy)
Number of subjects: 314
Study 34538087 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (without monitoring and drug adjustment)
Number of subjects: 314
Study 34538087 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 314
Study 34538087 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 314
Study 37257216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg/day for 14 days, then tapered to 10 mg for 1 month, followed by 5 mg/day for 2 months.
Number of subjects: 50
Study 37257216 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 20 mg/day for 14 days, then tapered to 5 mg for 2 months.
Number of subjects: 50
Study 34444526 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-rate feedback infusion (VFIM) of fentanyl/ropivacaine, basal infusion rate adjusted by 0.5 mL/h increase and 0.3 mL/h decrease
Number of subjects: 72
Study 34444526 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed-rate basal infusion (CFIM) of fentanyl/ropivacaine, fixed basal infusion rate of 5 mL/h
Number of subjects: 72
Study 34444526 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-rate feedback infusion (VFIM)
Number of subjects: 72
Study 34444526 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed-rate basal infusion (CFIM)
Number of subjects: 72
Study 35265033 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 288
Study 35265033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 32109884 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sets of 6 repetitions of flywheel EOL half-squats
Number of subjects: 13
Study 32109884 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of 6 repetitions of flywheel EOL half-squats
Number of subjects: 13
Study 32109884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set of 6 repetitions of flywheel EOL half-squats
Number of subjects: 13
Study 32109884 — intervention group
Group type: COMPARATOR
Intervention: Control (no PAP)
Number of subjects: 13
Study 33380195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone channelling
Number of subjects: 94
Study 33380195 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 94
Study 32056951 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate (SCC)
Number of subjects: 16
Study 35968574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction (Group II)
Number of subjects: 58
Study 35968574 — intervention group
Group type: COMPARATOR
Intervention: Isolated ACL reconstruction (Group I)
Number of subjects: 58
Study 33479112 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 35064721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3119
Study 35064721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3119
Study 35064721 — intervention group
Group type: COMPARATOR
Intervention: Higher UA (≥6.8 mg/dl)
Number of subjects: 3119
Study 34198658 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (habit formation techniques)
Number of subjects: 13
Study 34198658 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 616037861 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance visual acuity
Number of subjects: 85
Study 616037861 — intervention group
Group type: EXPERIMENTAL
Intervention: Near visual acuity
Number of subjects: 85
Study 616037861 — intervention group
Group type: EXPERIMENTAL
Intervention: Interocular visual acuity difference
Number of subjects: 85
Study 35675470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT
Number of subjects: 1150
Study 35675470 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1150
Study 34782796 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprophos (betamethasone)
Number of subjects: 150
Study 34782796 — intervention group
Group type: EXPERIMENTAL
Intervention: Depomedrone (methylprednisolone)
Number of subjects: 150
Study 34782796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone
Number of subjects: 150
Study 34782796 — intervention group
Group type: COMPARATOR
Intervention: Diprophos vs Depomedrone
Number of subjects: 150
Study 34782796 — intervention group
Group type: COMPARATOR
Intervention: Diprophos vs Ozone
Number of subjects: 150
Study 34782796 — intervention group
Group type: COMPARATOR
Intervention: Ozone vs Spondylolisthesis and Disc Herniation
Number of subjects: 150
Study 34343214 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC1 expression in patients with lymphatic metastasis
Number of subjects: 297
Study 34343214 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC1 expression in middle-aged group with lymphatic metastasis
Number of subjects: 297
Study 34343214 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC1 level higher than 1.4 in middle-aged group
Number of subjects: 297
Study 34343214 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC1 expression in 64-75 age group
Number of subjects: 297
Study 34343214 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC1 expression in populations younger than 64 or older than 75
Number of subjects: 297
Study 36183135 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 194
Study 36183135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 34020509 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2646264 (0.5% or 1% ww)
Number of subjects: 34
Study 34020509 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2646264 (1%)
Number of subjects: 34
Study 34020509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32234755 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9496 250 mg twice daily for 5-14 days
Number of subjects: 46
Study 32234755 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 500 mg on day 1
Number of subjects: 46
Study 35521825 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h meals service
Number of subjects: 76
Study 35521825 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein‐rich meal service
Number of subjects: 76
Study 35521825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation meal service
Number of subjects: 76
Study 35521825 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 76
Study 33428686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine A (CsA)
Number of subjects: 50
Study 33428686 — intervention group
Group type: COMPARATOR
Intervention: 0.5% carboxymethyl cellulose (CMC)
Number of subjects: 50
Study 34322079 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI combined with DSA-guided monitoring (intervention group, n = 127)
Number of subjects: 255
Study 34322079 — intervention group
Group type: COMPARATOR
Intervention: Standard group (PSI monitoring, n = 128)
Number of subjects: 255
Study 34322079 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study 33158822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 supplementation (1600 or 800 IU/day for 2 years)
Number of subjects: 2590
Study 33158822 — intervention group
Group type: COMPARATOR
Intervention: Regular follow-up
Number of subjects: 2590
Study 34303843 — intervention group
Group type: EXPERIMENTAL
Intervention: Open testing policies
Number of subjects: 0
Study 34303843 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized testing
Number of subjects: 0
Study 34303843 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalizing counts by testing rate
Number of subjects: 0
Study 34303843 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions
Number of subjects: 0
Study 32441875 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention to improve maternal and child outcomes
Number of subjects: 112
Study 32441875 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 112
Study 35227399 — intervention group
Group type: EXPERIMENTAL
Intervention: COS‐P (Circle of Security‐Parenting Intervention)
Number of subjects: 85
Study 35227399 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 85
Study 32751219 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol olive oil (HPOO) - 60 mL/day (360 mg/kg polyphenols)
Number of subjects: 50
Study 32751219 — intervention group
Group type: COMPARATOR
Intervention: Low polyphenol olive oil (LPOO) - 60 mL/day (86 mg/kg polyphenols)
Number of subjects: 50
Study 35172560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (RM)
Number of subjects: 240
Study 35172560 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 240
Study 33576820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (8000 mg)
Number of subjects: 214
Study 33576820 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (50 mg)
Number of subjects: 214
Study 33576820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ascorbic acid and zinc gluconate
Number of subjects: 214
Study 33576820 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 35194193 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline/cyclophosphamide‐taxane‐containing chemotherapy (AC‐T)
Number of subjects: 5924
Study 35194193 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/cyclophosphamide (TC6)
Number of subjects: 5924
Study 34146473 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-cell oral cholera vaccine (OCV)
Number of subjects: 268896
Study 34146473 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 268896
Study 32195655 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge home nurse visit
Number of subjects: 33
Study 32195655 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 33
Study 35079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with red (λ 660 nm) and infra-red laser therapy (λ 808 nm) applied immediately and 3 and 7 days after surgery.
Number of subjects: 20
Study 35079918 — intervention group
Group type: COMPARATOR
Intervention: Control side (no irradiation).
Number of subjects: 20
Study 33314251 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginalizing estimates of conditional odds ratios
Number of subjects: 0
Study 33314251 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginalizing estimates of conditional hazard ratios
Number of subjects: 0
Study 35538398 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + D + metformin (n=39)
Number of subjects: 788
Study 35538398 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + D (n=357)
Number of subjects: 788
Study 35538398 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + metformin (n=29)
Number of subjects: 788
Study 35538398 — intervention group
Group type: COMPARATOR
Intervention: ADT alone (n=363)
Number of subjects: 788
Study 33637085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis + standardized education and exercise (CRYO)
Number of subjects: 94
Study 33637085 — intervention group
Group type: COMPARATOR
Intervention: Sham + standardized education and exercise (SHAM)
Number of subjects: 94
Study 33814250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous bone only (C-only)
Number of subjects: 98
Study 33814250 — intervention group
Group type: COMPARATOR
Intervention: Corticocancellous (CC) grafting
Number of subjects: 98
Study 33228757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer intervention
Number of subjects: 1984
Study 33228757 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1984
Study 32538252 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg MDMA-HCl)
Number of subjects: 25
Study 32538252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg ascorbic acid)
Number of subjects: 25
Study 32538252 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 25
Study 33080378 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) group intervention
Number of subjects: 240
Study 33080378 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) control group
Number of subjects: 240
Study 34666854 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP (20 g)
Number of subjects: 15
Study 34666854 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP (40 g)
Number of subjects: 15
Study 34666854 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP (60 g)
Number of subjects: 15
Study 34024503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplement
Number of subjects: 18
Study 34024503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33046053 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid therapy (5-day standard treatment)
Number of subjects: 318
Study 33046053 — intervention group
Group type: COMPARATOR
Intervention: Low-dose corticosteroid therapy (eosinophil-guided intervention)
Number of subjects: 318
Study 34991417 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump technique
Number of subjects: 130
Study 34991417 — intervention group
Group type: COMPARATOR
Intervention: Seton technique
Number of subjects: 130
Study 33515770 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening (annual MRI and biennial mammography)
Number of subjects: 412
Study 33515770 — intervention group
Group type: COMPARATOR
Intervention: Mammography screening (annual mammography)
Number of subjects: 412
Study 34793361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (2 d/wk)
Number of subjects: 70
Study 34793361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HIIT (2 d/wk)
Number of subjects: 70
Study 34793361 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) (physical activity recommendations)
Number of subjects: 70
Study 32920297 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals (67 E% fat)
Number of subjects: 20
Study 32920297 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meals (16 E% fat)
Number of subjects: 20
Study 35818238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-mini percutaneous nephrolithotomy combined with ShuoTong ureteroscopy
Number of subjects: 42
Study 35818238 — intervention group
Group type: COMPARATOR
Intervention: Ultra-mini percutaneous nephrolithotomy
Number of subjects: 42
Study 34498056 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL) 200 mg once daily for 12 weeks
Number of subjects: 47
Study 34498056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanraplenib (LANRA) 30 mg once daily for 12 weeks
Number of subjects: 47
Study 34498056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) once daily for 12 weeks
Number of subjects: 47
Study 35130320 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments (SMAs)
Number of subjects: 24
Study 34836025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocovid (200 mg twice daily)
Number of subjects: 88
Study 34836025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 32708511 — intervention group
Group type: EXPERIMENTAL
Intervention: KW3110
Number of subjects: 88
Study 32708511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 36267362 — intervention group
Group type: EXPERIMENTAL
Intervention: CONT-MMI (continuation of low-dose methimazole therapy at 2.5-5 mg/day)
Number of subjects: 184
Study 36267362 — intervention group
Group type: COMPARATOR
Intervention: DISCONT-MMI (discontinuation of low-dose methimazole therapy)
Number of subjects: 184
Study 36267362 — intervention group
Group type: EXPERIMENTAL
Intervention: CONT-MMI
Number of subjects: 184
Study 36267362 — intervention group
Group type: COMPARATOR
Intervention: DISCONT-MMI
Number of subjects: 184
Study 35793833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab (1800 mg; three divided doses, q8h, within 24 hours)
Number of subjects: 520
Study 35793833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 33359752 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes receiving metformin
Number of subjects: 4393
Study 33359752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetes
Number of subjects: 4393
Study 35964207 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with visual feedback and rhythmic auditory cue (VF+RAC)
Number of subjects: 32
Study 35964207 — intervention group
Group type: COMPARATOR
Intervention: Control group (treadmill training without visual and auditory stimulation)
Number of subjects: 32
Study 33957195 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% Ruxolitinib cream
Number of subjects: 1249